StockData

MoonLake Immunotherapeutics vs Spyre Therapeutics

MLTX and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MLTX and SYRE compare

Spyre Therapeutics is the larger company, worth 8.6 times as much as MoonLake Immunotherapeutics ($8.3B against $957M).

Spyre Therapeutics scores higher on the StockData Score (7 against 1 for MoonLake Immunotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMLTXSYRE
Size and price
Market cap$957M$8.3B
Share price$11.25$93.81
Change, 1 year−11.9%299%
Change, 5 years14.0%−41.8%
Beta (5Y)1.821.99
Employees130102
StockData Score
Total score17 (better)
Valuation score00
Growth score00
Performance score01 (better)
Health score16 (better)
Dividend score00
Valuation
P/B2.2× (better)7.5×
FCF yield−23.5%–
Profitability
Return on equity−67.4%−23.0% (better)
Financial health
Debt / equity–0.00
Interest coverage−26.6×–
Current ratio12.5618.53 (better)
Altman Z-score2.0568.16 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.3%109%
Held by insiders59.9%20.3%
Insider net buying, 12 months−$83.0M (better)−$442M
Short interest, % of float16.0%16.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.